Press releases
- Hansa Biopharma interim report January-March 2024
- Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance
- Hansa Biopharma publishes 2023 Annual and Sustainability Reports
- Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer
- Hansa Biopharma Year-end report January-December 2023
More ▼
Key statistics
As of last trade, Hansa Biopharma AB (0RC7:LSE) traded at 28.82, 38.96% above the 52 week low of 20.74 set on Oct 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 28.77 |
---|---|
High | -- |
Low | -- |
Bid | 28.26 |
Offer | 29.70 |
Previous close | 28.82 |
Average volume | 3.58k |
---|---|
Shares outstanding | 52.67m |
Free float | 48.58m |
P/E (TTM) | -- |
Market cap | 1.52bn SEK |
EPS (TTM) | -16.07 SEK |
Data delayed at least 20 minutes, as of Apr 30 2024 17:34 BST.
More ▼